The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...
Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...
After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.
Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% ...
A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...
New research into acute myeloid leukemia could change future treatment approaches.
Rare diseases are widely underrecognized. Individually uncommon, they affect nearly 10% of Americans, with diagnosis often ...
FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...
BARCELONA, Spain, Feb. 10, 2026 /PRNewswire/ -- Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, today announced the ...
CLL is staged from 0 to 4 using the Rai system based on factors like lymphocyte count and organ enlargement. The earlier stages of CLL, like stage 0 and stage 1, often have a good prognosis and slow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results